

# CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands

## 2019 ANNUAL HIV TESTING REPORT

### OVERVIEW

The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates data on CDC-funded HIV testing and prevention activities reported through the National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reporting system, EvaluationWeb®. These data are used to assess the impact of CDC-funded HIV testing efforts, inform programmatic activities, and document the progress of programs toward local, state, and national HIV prevention goals.

This report describes the demographics of persons tested, newly diagnosed with HIV, and linked to HIV medical care in the United States, Puerto Rico, and U.S. Virgin Islands in 2019. Data presented in this report include HIV test-level data from 60 state and local health departments (HDs) and 100 community-based organizations (CBOs) reported to CDC through EvaluationWeb® as of September 15, 2020. Several jurisdictions reported incomplete or delayed reporting of 2019 HIV test-level data due to the deployment of key HIV prevention staff to SARS-CoV2 response activities at the time of data submission in 2020.



### CDC-funded HIV testing by setting & site type\*

A total of 2,452,507 CDC-funded HIV tests were conducted in 2019. Most were conducted in health care settings (74%) such as Sexually Transmitted Disease (STD) Clinics and Community Health Centers. The tables below show the number of tests conducted and the percentage of tests resulting in new diagnoses (newly diagnosed % positivity) by site type.

	TESTS (% POSITIVITY)		TESTS (% POSITIVITY)
<b>Health care setting</b>	<b>1,752,586 (0.3%)</b>	<b>Non-health care setting</b>	<b>632,757 (0.6%)</b>
Emergency Department	293,815 (0.2%)	HIV Testing Site	288,853 (0.7%)
STD Clinics	536,043 (0.4%)	Community Settings	192,943 (0.5%)
Community Health Centers	450,497 (0.3%)	Correctional Facilities, Non-health care	50,324 (0.3%)
Correctional Clinics	110,731 (0.2%)	Other <sup>b</sup>	100,637 (0.4%)
Other <sup>a</sup>	361,500 (0.3%)		

\* 54,401 tests were conducted in mobile settings and 12,763 tests were missing information on site type.


<sup>a</sup> Health care sites other than those specified where medical services are provided including primary care clinics, substance abuse treatment facilities, pharmacies, dental clinics, TB clinics, and inpatient hospitals.

<sup>b</sup> Non-health care sites other than those specified where prevention services are conducted including health department field visits and syringe exchange programs.


## Newly diagnosed HIV positivity by age, gender, race/ethnicity and population group

Among the 2,452,507 CDC-funded HIV tests conducted, 9,188 (0.4%) persons were newly diagnosed with HIV. The figures below show the newly diagnosed percent positivity (i.e., percentage of CDC-funded tests conducted that identified persons newly diagnosed with HIV) by demographic characteristics and population groups. Additional information, including number of tests conducted by category, can be found in Appendix Table 4.


### AGE <sup>a</sup>




### GENDER <sup>b</sup>



### RACE & ETHNICITY <sup>c</sup>



### POPULATION GROUP in non-health care settings <sup>d</sup>



<sup>a</sup> "< 13 years" category is not shown.

<sup>b</sup> Transgender is defined as a person whose current gender identity differs from their sex assigned at birth. "Another gender" category is not shown.

<sup>c</sup> "Multi-race" category is not shown.

<sup>d</sup> Restricted to non-health care settings because data on population groups are required for all CDC-funded tests performed in non-health care settings but only required for HIV-positive tests in health care settings. Categories are mutually exclusive and based on behavioral risk in past 12 months under the old NHM&E reporting requirements and in past 5 years under the new requirements. For more information, see Technical Notes.

## CDC-funded HIV testing in 60 jurisdictions

Among 9,188 persons newly diagnosed with HIV, 71% were linked to HIV medical care within 30 days of their positive test and 81% were interviewed for Partner Services. The reported percentages\* varied by jurisdiction, as shown in Table 1 below.

**Table 1. CDC-funded HIV testing and outcomes among persons newly diagnosed with HIV in the United States, Puerto Rico, and U.S. Virgin Islands, 2019**

Jurisdictions	CDC-funded HIV tests			
	Number of HIV tests conducted in 2019	Number (%) of persons newly diagnosed with HIV	Percentage of persons newly diagnosed with HIV linked to HIV medical care within 30 days*	Percentage of persons newly diagnosed with HIV interviewed for partner services*
Alabama	80,027	233 (0.3%)	24%	84%
Alaska	1,678	3 (0.2%)	67%	100%
Arizona	60,880	225 (0.4%)	76%	91%
Arkansas	5,340	6 (0.1%)	100%	50%
California				
Los Angeles	132,345	859 (0.6%)	57%	63%
San Francisco	30,577	70 (0.2%)	86%	62%
California (excludes Los Angeles and San Francisco)	35,356	259 (0.7%)	73%	46%
Colorado	1,616	10 (0.6%)	43%	89%
Connecticut	70,260	93 (0.1%)	89%	86%
Delaware	10,857	21 (0.2%)	86%	71%
District of Columbia	27,059	160 (0.6%)	82%	42%
Florida	242,643	1,210 (0.5%)	66%	82%
Georgia	133,001	808 (0.6%)	78%	83%
Hawaii	3,227	3 (0.1%)	67%	100%
Idaho	3,703	9 (0.2%)	78%	100%
Illinois				
Chicago	52,992	75 (0.1%)	60%	56%
Illinois (excludes Chicago)	2,879	4 (0.1%)	67%	100%
Indiana	25,196	4 (0.0%)	33%	100%
Iowa	11,668	16 (0.1%)	88%	100%
Kansas	18,132	43 (0.2%)	88%	91%
Kentucky	18,908	10 (0.1%)	75%	100%
Louisiana	117,600	342 (0.3%)	85%	97%
Maine	1,840	5 (0.3%)	80%	100%
Maryland				
Baltimore	46,148	131 (0.3%)	61%	61%
Maryland (excludes Baltimore)	39,119	64 (0.2%)	75%	77%
Massachusetts	42,222	117 (0.3%)	78%	92%
Michigan	47,346	170 (0.4%)	87%	89%
Minnesota	4,318	8 (0.2%)	20%	100%
Mississippi	50,312	202 (0.4%)	56%	87%
Missouri	54,980	156 (0.3%)	61%	92%
Montana	2,563	0 (0.0%)	n/a	n/a
Nebraska	8,436	26 (0.3%)	60%	100%
Nevada	24,812	167 (0.7%)	76%	91%

## CDC-funded HIV testing in 60 jurisdictions (continued)

**Table 1. CDC-funded HIV testing and outcomes among persons newly diagnosed with HIV in the United States, Puerto Rico, and U.S. Virgin Islands, 2019 (continued)**

Jurisdictions	CDC-funded HIV tests			
	Number of HIV tests conducted in 2019	Number (%) of persons newly diagnosed with HIV	Percentage linked to HIV medical care within 30 days*	Percentage interviewed for Partner Services*
New Hampshire	1,260	5 (0.4%)	100%	75%
New Jersey	26,598	140 (0.5%)	94%	76%
New Mexico	8,090	34 (0.4%)	76%	91%
New York				
New York City	91,283	430 (0.5%)	85%	73%
New York (excludes New York City)	25,323	127 (0.5%)	86%	85%
North Carolina	40,778	85 (0.2%)	68%	84%
North Dakota	5,609	7 (0.1%)	29%	86%
Ohio	16,718	232 (1.4%)	81%	94%
Oklahoma	4,579	19 (0.4%)	88%	67%
Oregon	10,404	41 (0.4%)	79%	94%
Pennsylvania				
Philadelphia	48,275	164 (0.3%)	83%	70%
Pennsylvania (excludes Philadelphia)	73,301	155 (0.2%)	79%	86%
Rhode Island	2,788	2 (0.1%)	100%	100%
South Carolina	62,884	272 (0.4%)	58%	89%
South Dakota	1,606	1 (0.1%)	n/c	100%
Tennessee	111,836	326 (0.3%)	54%	81%
Texas				
Houston	97,090	398 (0.4%)	79%	85%
Texas (excludes Houston)	288,729	765 (0.3%)	66%	73%
Utah	2,384	8 (0.3%)	100%	100%
Vermont	338	2 (0.6%)	100%	100%
Virginia	65,586	223 (0.3%)	77%	83%
Washington	14,471	57 (0.4%)	88%	62%
West Virginia	6,505	26 (0.4%)	73%	93%
Wisconsin	14,323	25 (0.2%)	88%	92%
Wyoming	4,198	0 (0.0%)	n/a	n/a
Puerto Rico	17,631	128 (0.7%)	85%	90%
U.S. Virgin Islands	1,880	7 (0.4%)	71%	100%
<b>Total</b>	<b>2,452,507</b>	<b>9,188 (0.4%)</b>	<b>71%</b>	<b>81%</b>

n/a= not applicable; n/c=not able to calculate due to insufficient data

\* Reported percentages exclude tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

# CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands

## 2019 ANNUAL HIV TESTING REPORT

### TECHNICAL NOTES

Data presented in this report include HIV test-level data from 60 state and local health departments (HDs) and 100 community-based organizations (CBOs) directly funded by CDC through 5 funding opportunities ([PS15-1502](#), [PS15-1509](#), [PS17-1704](#), [PS19-1901](#) and [PS18-1802](#)) and reported to CDC through EvaluationWeb® as of September 15, 2020. CBOs funded through PS17-1704 transitioned to new NHM&E data reporting requirements (i.e., required set of variables and program indicators) beginning in April 2019. CBOs directly funded through PS15-1502 did not transition to new reporting requirements. For recipients that reported test-level data under both the old and new requirements, data were analyzed separately and resulting counts were combined in the tables and figures displayed.

### DEFINITIONS AND INTERPRETING THIS REPORT

- An HIV test is defined as a sequence of one or more HIV tests conducted to determine a person's HIV status.
- Total tests include only tests with negative or positive results; tests with discordant or inconclusive results are excluded.
- NHM&E data are collected at the test-level; therefore, data included in this report represent test records rather than individuals. Clients tested multiple times may be included in the data.
- A person with newly diagnosed HIV is defined as a person who tests positive on the current test (includes persons with unconfirmed preliminary positive rapid tests and persons with confirmed positive tests) and has no indication of a previous positive test.
- The reported percentage of persons linked to HIV medical care within 30 days is calculated by excluding tests with missing or unknown outcome data from the denominator, which likely overestimates actual linkage. Similarly, the reported percentage of persons interviewed for partner services is calculated by excluding tests with missing or unknown outcome data from the denominator, which likely overestimates the actual percentage interviewed.
- Procedures for data collection and verification vary among jurisdictions. For example, some jurisdictions accept a client's self-report as adequate evidence that the client is newly diagnosed or has been linked to HIV medical care; whereas others require a cross-check with the surveillance system to rule out prior diagnosis or to verify linkage to care.
- Jurisdictions vary considerably in resources available for HIV prevention and in the contexts in which they operate, which can affect program capacity. For example, some jurisdictions may receive state and local funds in addition to federal funds, whereas others may not. Examples of contextual issues that may affect program capacity include HIV prevalence, geography, political environment, laws and regulations, program infrastructure, surveillance system capacity, and accessibility to surveillance data to help guide program activities.
- Because the population accessing HIV testing services at publicly funded sites is not necessarily representative of all persons who are tested for HIV in the United States, these findings should not be applied to the general population.

### ACKNOWLEDGEMENTS

Publication of this report would not have been possible without the hard work and dedication of state and local health departments and community-based organizations that collected and submitted the HIV test-level data. This report was prepared by Nicoline Collins, Guoshen Wang, Songli Xu, Carolyn Wright, and Shubha Rao of the Program Evaluation Branch in the Division of HIV/AIDS Prevention. We also acknowledge the contributions of Lisa Belcher and Janet Heitgerd of the Program Evaluation Branch; the Quantitative Sciences and Data Management Branch; and the Prevention Program Branch for their contribution toward monitoring and strengthening HIV prevention efforts in state and local health departments and community-based organizations.

Suggested citation: Centers for Disease Control and Prevention. *CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019*. <http://www.cdc.gov/hiv/library/reports/index.html>. Published March 2021. Accessed [Date].

# CDC-Funded HIV Testing in the United States, Puerto Rico, and U.S. Virgin Islands

## 2019 ANNUAL HIV TESTING REPORT

### APPENDIX: DETAILED TABLES

**Table 1.** Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019

**Table 2.** Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019

**Table 3.** CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019

**Table 4.** CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019

**Table 5.** CDC-funded HIV testing and interview for partner services among persons newly diagnosed with HIV, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019

**Table 6.** CDC-funded HIV testing and linkage to HIV medical care among persons previously diagnosed with HIV not in HIV medical care, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019

#### **For more information, contact:**

Division of HIV/AIDS Prevention  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
U.S. Centers for Disease Control and Prevention  
1600 Clifton Road NE, MS E-59, Atlanta, GA 30333  
Phone: 1-800-CDC-INFO  
Web address: <http://www.cdc.gov/HIV>

National HIV Prevention Program Monitoring and Evaluation Service Center  
Phone: 1-855-374-7310, Email: [NHMEservice@cdc.gov](mailto:NHMEservice@cdc.gov)

**Table 1. Number of CDC-funded HIV tests and HIV positivity, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019**

CDC-funded Jurisdiction	HIV-positive tests <sup>b</sup>								
	HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>c</sup>		Previously diagnosed HIV-positive tests <sup>d</sup>		Unable to determine prior HIV status <sup>e</sup>		Total	
	No.	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Alabama	80,027	233	(0.3)	430	(0.5)	218	(0.3)	881	(1.1)
Alaska	1,678	3	(0.2)	0	(0.0)	0	(0.0)	3	(0.2)
Arizona	60,880	225	(0.4)	72	(0.1)	63	(0.1)	360	(0.6)
Arkansas	5,340	6	(0.1)	12	(0.2)	113	(2.1)	131	(2.5)
California									
Los Angeles	132,345	859	(0.6)	458	(0.3)	46	(0.0)	1,363	(1.0)
San Francisco	30,577	70	(0.2)	278	(0.9)	7	(0.0)	355	(1.2)
California (excludes Los Angeles and San Francisco)	35,356	259	(0.7)	115	(0.3)	33	(0.1)	407	(1.2)
Colorado	1,616	10	(0.6)	10	(0.6)	0	(0.0)	20	(1.2)
Connecticut	70,260	93	(0.1)	25	(0.0)	4	(0.0)	122	(0.2)
Delaware	10,857	21	(0.2)	13	(0.1)	0	(0.0)	34	(0.3)
District of Columbia	27,059	160	(0.6)	125	(0.5)	3	(0.0)	288	(1.1)
Florida	242,643	1,210	(0.5)	1,482	(0.6)	211	(0.1)	2,903	(1.2)
Georgia	133,001	808	(0.6)	293	(0.2)	77	(0.1)	1,178	(0.9)
Hawaii	3,227	3	(0.1)	0	(0.0)	26	(0.8)	29	(0.9)
Idaho	3,703	9	(0.2)	1	(0.0)	2	(0.1)	12	(0.3)
Illinois									
Chicago	52,992	75	(0.1)	227	(0.4)	291	(0.5)	593	(1.1)
Illinois (excludes Chicago)	2,879	4	(0.1)	0	(0.0)	2	(0.1)	6	(0.2)
Indiana	25,196	4	(0.0)	0	(0.0)	118	(0.5)	122	(0.5)
Iowa	11,668	16	(0.1)	3	(0.0)	2	(0.0)	21	(0.2)
Kansas	18,132	43	(0.2)	5	(0.0)	3	(0.0)	51	(0.3)
Kentucky	18,908	10	(0.1)	9	(0.0)	94	(0.5)	113	(0.6)
Louisiana	117,600	342	(0.3)	767	(0.7)	20	(0.0)	1,129	(1.0)
Maine	1,840	5	(0.3)	0	(0.0)	1	(0.1)	6	(0.3)
Maryland									
Baltimore	46,148	131	(0.3)	408	(0.9)	0	(0.0)	539	(1.2)
Maryland (excludes Baltimore)	39,119	64	(0.2)	88	(0.2)	0	(0.0)	152	(0.4)
Massachusetts	42,222	117	(0.3)	513	(1.2)	0	(0.0)	630	(1.5)
Michigan	47,346	170	(0.4)	107	(0.2)	8	(0.0)	285	(0.6)
Minnesota	4,318	8	(0.2)	15	(0.3)	8	(0.2)	31	(0.7)
Mississippi	50,312	202	(0.4)	103	(0.2)	3	(0.0)	308	(0.6)
Missouri	54,980	156	(0.3)	180	(0.3)	46	(0.1)	382	(0.7)
Montana	2,563	0	(0.0)	0	(0.0)	6	(0.2)	6	(0.2)
Nebraska	8,436	26	(0.3)	8	(0.1)	1	(0.0)	35	(0.4)
Nevada	24,812	167	(0.7)	160	(0.6)	18	(0.1)	345	(1.4)

CDC-funded Jurisdiction	HIV-positive tests <sup>b</sup>								
	HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>c</sup>		Previously diagnosed HIV-positive tests <sup>d</sup>		Unable to determine prior HIV status <sup>e</sup>		Total	
	No.	No.	(%)	No.	(%)	No.	(%)	No.	(%)
New Hampshire	1,260	5	(0.4)	0	(0.0)	0	(0.0)	5	(0.4)
New Jersey	26,598	140	(0.5)	123	(0.5)	40	(0.2)	303	(1.1)
New Mexico	8,090	34	(0.4)	18	(0.2)	11	(0.1)	63	(0.8)
New York									
New York City	91,283	430	(0.5)	371	(0.4)	43	(0.0)	844	(0.9)
New York (excludes New York City)	25,323	127	(0.5)	251	(1.0)	27	(0.1)	405	(1.6)
North Carolina	40,778	85	(0.2)	184	(0.5)	4	(0.0)	273	(0.7)
North Dakota	5,609	7	(0.1)	6	(0.1)	2	(0.0)	15	(0.3)
Ohio	16,718	232	(1.4)	73	(0.4)	1	(0.0)	306	(1.8)
Oklahoma	4,579	19	(0.4)	5	(0.1)	129	(2.8)	153	(3.3)
Oregon	10,404	41	(0.4)	16	(0.2)	0	(0.0)	57	(0.5)
Pennsylvania									
Philadelphia	48,275	164	(0.3)	257	(0.5)	74	(0.2)	495	(1.0)
Pennsylvania (excludes Philadelphia)	73,301	155	(0.2)	492	(0.7)	38	(0.1)	685	(0.9)
Rhode Island	2,788	2	(0.1)	1	(0.0)	1	(0.0)	4	(0.1)
South Carolina	62,884	272	(0.4)	133	(0.2)	60	(0.1)	465	(0.7)
South Dakota	1,606	1	(0.1)	0	(0.0)	7	(0.4)	8	(0.5)
Tennessee	111,836	326	(0.3)	613	(0.5)	68	(0.1)	1,007	(0.9)
Texas									
Houston	97,090	398	(0.4)	904	(0.9)	0	(0.0)	1,302	(1.3)
Texas (excludes Houston)	288,729	765	(0.3)	1,549	(0.5)	2	(0.0)	2,316	(0.8)
Utah	2,384	8	(0.3)	1	(0.0)	0	(0.0)	9	(0.4)
Vermont	338	2	(0.6)	0	(0.0)	0	(0.0)	2	(0.6)
Virginia	65,586	223	(0.3)	123	(0.2)	1	(0.0)	347	(0.5)
Washington	14,471	57	(0.4)	8	(0.1)	28	(0.2)	93	(0.6)
West Virginia	6,505	26	(0.4)	18	(0.3)	15	(0.2)	59	(0.9)
Wisconsin	14,323	25	(0.2)	18	(0.1)	18	(0.1)	61	(0.4)
Wyoming	4,198	0	(0.0)	0	(0.0)	8	(0.2)	8	(0.2)
Puerto Rico	17,631	128	(0.7)	89	(0.5)	7	(0.0)	224	(1.3)
U.S. Virgin Islands	1,880	7	(0.4)	5	(0.3)	0	(0.0)	12	(0.6)
<b>Total</b>	<b>2,452,507</b>	<b>9,188</b>	<b>(0.4)</b>	<b>11,165</b>	<b>(0.5)</b>	<b>2,008</b>	<b>(0.1)</b>	<b>22,361</b>	<b>(0.9)</b>

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb<sup>®</sup> as of September 15, 2020.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> Includes unconfirmed preliminary positive rapid tests and confirmed positive tests.

<sup>c</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>d</sup> A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV test or evidence of a previous positive test is found on review of other data sources.

<sup>e</sup> A positive test that was missing information on prior HIV status or was reported as unable to determine prior HIV status (i.e., the HIV surveillance system was not checked, no other data sources were reviewed and there is no information from the client about previous HIV test results).



**Table 2. Number of CDC-funded HIV tests and newly diagnosed HIV positivity in health care and non-health care settings, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019**

CDC-funded Jurisdiction	Health care settings				Non-health care settings			
	HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>		HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Alabama	26,387	(33.0)	77	(0.3)	53,640	(67.0)	156	(0.3)
Alaska	250	(14.9)	0	(0.0)	1,341	(79.9)	3	(0.2)
Arizona	46,632	(76.6)	162	(0.3)	14,248	(23.4)	63	(0.4)
Arkansas	1,183	(22.2)	0	(0.0)	4,156	(77.8)	6	(0.1)
California								
Los Angeles	64,338	(48.6)	419	(0.7)	34,291	(25.9)	261	(0.8)
San Francisco	27,162	(88.8)	57	(0.2)	3,415	(11.2)	13	(0.4)
California (excludes Los Angeles and San Francisco)	18,833	(53.3)	164	(0.9)	10,059	(28.5)	64	(0.6)
Colorado	0	(0.0)	0	(0.0)	1,615	(99.9)	10	(0.6)
Connecticut	67,545	(96.1)	78	(0.1)	2,715	(3.9)	15	(0.6)
Delaware	6,695	(61.7)	13	(0.2)	4,162	(38.3)	8	(0.2)
District of Columbia	13,734	(50.8)	65	(0.5)	13,222	(48.9)	89	(0.7)
Florida	136,717	(56.3)	575	(0.4)	99,504	(41.0)	617	(0.6)
Georgia	79,553	(59.8)	334	(0.4)	52,855	(39.7)	472	(0.9)
Hawaii	1,361	(42.2)	2	(0.1)	1,866	(57.8)	1	(0.1)
Idaho	1,956	(52.8)	6	(0.3)	1,747	(47.2)	3	(0.2)
Illinois								
Chicago	44,576	(84.1)	22	(0.0)	8,416	(15.9)	53	(0.6)
Illinois (excludes Chicago)	1,839	(63.9)	3	(0.2)	1,040	(36.1)	1	(0.1)
Indiana	13,961	(55.4)	4	(0.0)	11,235	(44.6)	0	(0.0)
Iowa	9,526	(81.6)	13	(0.1)	2,142	(18.4)	3	(0.1)
Kansas	12,716	(70.1)	27	(0.2)	3,665	(20.2)	16	(0.4)
Kentucky	13,862	(73.3)	8	(0.1)	5,046	(26.7)	2	(0.0)
Louisiana	99,536	(84.6)	208	(0.2)	17,947	(15.3)	134	(0.7)
Maine	1,232	(67.0)	3	(0.2)	608	(33.0)	2	(0.3)
Maryland								
Baltimore	37,644	(81.6)	100	(0.3)	8,504	(18.4)	31	(0.4)
Maryland (excludes Baltimore)	35,066	(89.6)	58	(0.2)	4,053	(10.4)	6	(0.1)
Massachusetts	39,140	(92.7)	103	(0.3)	3,082	(7.3)	14	(0.5)
Michigan	42,752	(90.3)	132	(0.3)	4,594	(9.7)	38	(0.8)
Minnesota	807	(18.7)	0	(0.0)	3,511	(81.3)	8	(0.2)
Mississippi	38,170	(75.9)	194	(0.5)	3,182	(6.3)	6	(0.2)
Missouri	45,958	(83.6)	119	(0.3)	9,022	(16.4)	37	(0.4)
Montana	1,021	(39.8)	0	(0.0)	1,541	(60.1)	0	(0.0)
Nebraska	6,024	(71.4)	19	(0.3)	2,412	(28.6)	7	(0.3)
Nevada	9,044	(36.5)	42	(0.5)	15,768	(63.5)	125	(0.8)
New Hampshire	652	(51.7)	3	(0.5)	608	(48.3)	2	(0.3)

CDC-funded Jurisdiction	Health care settings				Non-health care settings			
	HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>		HIV tests <sup>a</sup>		Newly diagnosed HIV-positive tests <sup>b</sup>	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)
New Jersey	14,413	(54.2)	91	(0.6)	12,185	(45.8)	49	(0.4)
New Mexico	6,667	(82.4)	24	(0.4)	1,423	(17.6)	10	(0.7)
New York								
New York City	82,866	(90.8)	336	(0.4)	7,619	(8.3)	93	(1.2)
New York (excludes New York City)	5,441	(21.5)	73	(1.3)	17,916	(70.7)	51	(0.3)
North Carolina	8,419	(20.6)	16	(0.2)	32,304	(79.2)	68	(0.2)
North Dakota	136	(2.4)	0	(0.0)	5,473	(97.6)	7	(0.1)
Ohio	9,991	(59.8)	145	(1.5)	6,727	(40.2)	87	(1.3)
Oklahoma	354	(7.7)	0	(0.0)	4,222	(92.2)	19	(0.5)
Oregon	7,819	(75.2)	34	(0.4)	2,459	(23.6)	7	(0.3)
Pennsylvania								
Philadelphia	36,912	(76.5)	101	(0.3)	9,150	(19.0)	57	(0.6)
Pennsylvania (excludes Philadelphia)	67,032	(91.4)	146	(0.2)	6,268	(8.6)	9	(0.1)
Rhode Island	2	(0.1)	0	(0.0)	2,786	(99.9)	2	(0.1)
South Carolina	50,499	(80.3)	144	(0.3)	12,232	(19.5)	127	(1.0)
South Dakota	1,168	(72.7)	1	(0.1)	438	(27.3)	0	(0.0)
Tennessee	102,565	(91.7)	228	(0.2)	9,109	(8.1)	98	(1.1)
Texas								
Houston	91,156	(93.9)	280	(0.3)	5,876	(6.1)	118	(2.0)
Texas (excludes Houston)	233,195	(80.8)	429	(0.2)	53,533	(18.5)	328	(0.6)
Utah	2,344	(98.3)	8	(0.3)	40	(1.7)	0	(0.0)
Vermont	9	(2.7)	0	(0.0)	329	(97.3)	2	(0.6)
Virginia	52,420	(79.9)	140	(0.3)	11,754	(17.9)	83	(0.7)
Washington	7,232	(50.0)	36	(0.5)	7,239	(50.0)	21	(0.3)
West Virginia	4,703	(72.3)	8	(0.2)	1,802	(27.7)	18	(1.0)
Wisconsin	6,343	(44.3)	9	(0.1)	7,980	(55.7)	16	(0.2)
Wyoming	4,181	(99.6)	0	(0.0)	17	(0.4)	0	(0.0)
Puerto Rico	9,612	(54.5)	109	(1.1)	8,019	(45.5)	19	(0.2)
U.S. Virgin Islands	1,235	(65.7)	6	(0.5)	645	(34.3)	1	(0.2)
<b>Total</b>	<b>1,752,586</b>	<b>(71.5)</b>	<b>5,374</b>	<b>(0.3)</b>	<b>632,757</b>	<b>(25.8)</b>	<b>3,556</b>	<b>(0.6)</b>

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb® as of September 15, 2020.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

**Table 3. CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019**

CDC-funded Jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days <sup>c</sup>					
	All HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>d</sup>	Reported percentage <sup>e</sup> (%)
Alabama	80,027	233	(0.3)	48	149	36	(15.5)	197	(24.4)
Alaska	1,678	3	(0.2)	2	1	0	(0.0)	3	(66.7)
Arizona	60,880	225	(0.4)	165	53	7	(3.1)	218	(75.7)
Arkansas	5,340	6	(0.1)	1	0	5	(83.3)	1	(100.0)
California									
Los Angeles	132,345	859	(0.6)	381	285	193	(22.5)	666	(57.2)
San Francisco	30,577	70	(0.2)	55	9	6	(8.6)	64	(85.9)
California (excludes Los Angeles and San Francisco)	35,356	259	(0.7)	170	63	26	(10.0)	233	(73.0)
Colorado	1,616	10	(0.6)	3	4	3	(30.0)	7	(42.9)
Connecticut	70,260	93	(0.1)	80	10	3	(3.2)	90	(88.9)
Delaware	10,857	21	(0.2)	18	3	0	(0.0)	21	(85.7)
District of Columbia	27,059	160	(0.6)	73	16	71	(44.4)	89	(82.0)
Florida	242,643	1,210	(0.5)	384	194	632	(52.2)	578	(66.4)
Georgia	133,001	808	(0.6)	575	162	71	(8.8)	737	(78.0)
Hawaii	3,227	3	(0.1)	2	1	0	(0.0)	3	(66.7)
Idaho	3,703	9	(0.2)	7	2	0	(0.0)	9	(77.8)
Illinois									
Chicago	52,992	75	(0.1)	27	18	30	(40.0)	45	(60.0)
Illinois (excludes Chicago)	2,879	4	(0.1)	2	1	1	(25.0)	3	(66.7)
Indiana	25,196	4	(0.0)	1	2	1	(25.0)	3	(33.3)
Iowa	11,668	16	(0.1)	14	2	0	(0.0)	16	(87.5)
Kansas	18,132	43	(0.2)	38	5	0	(0.0)	43	(88.4)
Kentucky	18,908	10	(0.1)	6	2	2	(20.0)	8	(75.0)
Louisiana	117,600	342	(0.3)	250	45	47	(13.7)	295	(84.7)
Maine	1,840	5	(0.3)	4	1	0	(0.0)	5	(80.0)
Maryland									
Baltimore	46,148	131	(0.3)	76	48	7	(5.3)	124	(61.3)
Maryland (excludes Baltimore)	39,119	64	(0.2)	41	14	9	(14.1)	55	(74.5)
Massachusetts	42,222	117	(0.3)	80	22	15	(12.8)	102	(78.4)
Michigan	47,346	170	(0.4)	139	20	11	(6.5)	159	(87.4)
Minnesota	4,318	8	(0.2)	1	4	3	(37.5)	5	(20.0)
Mississippi	50,312	202	(0.4)	112	88	2	(1.0)	200	(56.0)
Missouri	54,980	156	(0.3)	55	35	66	(42.3)	90	(61.1)
Montana	2,563	0	----	0	0	0	----	0	----
Nebraska	8,436	26	(0.3)	9	6	11	(42.3)	15	(60.0)
Nevada	24,812	167	(0.7)	108	35	24	(14.4)	143	(75.5)

CDC-funded Jurisdiction	HIV tests			Linkage to HIV Medical Care in 30 days <sup>c</sup>					
	All HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>d</sup>	Reported percentage <sup>e</sup>
New Hampshire	1,260	5	(0.4)	3	0	2	(40.0)	3	(100.0)
New Jersey	26,598	140	(0.5)	132	8	0	(0.0)	140	(94.3)
New Mexico	8,090	34	(0.4)	25	8	1	(2.9)	33	(75.8)
New York									
New York City	91,283	430	(0.5)	334	58	38	(8.8)	392	(85.2)
New York (excludes New York City)	25,323	127	(0.5)	109	18	0	(0.0)	127	(85.8)
North Carolina	40,778	85	(0.2)	51	24	10	(11.8)	75	(68.0)
North Dakota	5,609	7	(0.1)	2	5	0	(0.0)	7	(28.6)
Ohio	16,718	232	(1.4)	179	42	11	(4.7)	221	(81.0)
Oklahoma	4,579	19	(0.4)	14	2	3	(15.8)	16	(87.5)
Oregon	10,404	41	(0.4)	30	8	3	(7.3)	38	(78.9)
Pennsylvania									
Philadelphia	48,275	164	(0.3)	126	25	13	(7.9)	151	(83.4)
Pennsylvania (excludes Philadelphia)	73,301	155	(0.2)	123	32	0	(0.0)	155	(79.4)
Rhode Island	2,788	2	(0.1)	2	0	0	(0.0)	2	(100.0)
South Carolina	62,884	272	(0.4)	156	113	3	(1.1)	269	(58.0)
South Dakota	1,606	1	(0.1)	0	0	1	(100.0)	0	----
Tennessee	111,836	326	(0.3)	168	142	16	(4.9)	310	(54.2)
Texas									
Houston	97,090	398	(0.4)	218	58	122	(30.7)	276	(79.0)
Texas (excludes Houston)	288,729	765	(0.3)	493	259	13	(1.7)	752	(65.6)
Utah	2,384	8	(0.3)	3	0	5	(62.5)	3	(100.0)
Vermont	338	2	(0.6)	2	0	0	(0.0)	2	(100.0)
Virginia	65,586	223	(0.3)	168	51	4	(1.8)	219	(76.7)
Washington	14,471	57	(0.4)	49	7	1	(1.8)	56	(87.5)
West Virginia	6,505	26	(0.4)	8	3	15	(57.7)	11	(72.7)
Wisconsin	14,323	25	(0.2)	22	3	0	(0.0)	25	(88.0)
Wyoming	4,198	0	----	0	0	0	----	0	----
Puerto Rico	17,631	128	(0.7)	106	18	4	(3.1)	124	(85.5)
U.S. Virgin Islands	1,880	7	(0.4)	5	2	0	(0.0)	7	(71.4)
<b>Total</b>	<b>2,452,507</b>	<b>9,188</b>	<b>(0.4)</b>	<b>5,455</b>	<b>2,186</b>	<b>1,547</b>	<b>(16.8)</b>	<b>7,641</b>	<b>(71.4)</b>

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb<sup>®</sup> as of September 15, 2020.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>c</sup> A person is considered linked to HIV medical care within 30 days if they have attended an appointment for HIV medical care within 30 days of diagnosis.

<sup>d</sup> Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days. This is the denominator used to calculate the reported percentage.

<sup>e</sup> Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

**Table 4. CDC-funded HIV testing and linkage to HIV medical care among persons newly diagnosed with HIV by demographic characteristics, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019**

Characteristics	HIV tests				Linkage to HIV medical care in 30 days <sup>c</sup>					
	All tests <sup>a</sup>	Percent of all tests (%)	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>d</sup>	Reported percentage <sup>e</sup> (%)
<b>Age at test (years)</b>										
<13	4,628	(0.2)	11	(0.2)	8	2	1	(9.1)	10	(80.0)
13-19	158,376	(6.5)	321	(0.2)	220	68	33	(10.3)	288	(76.4)
20-29	889,032	(36.2)	3,891	(0.4)	2,376	930	585	(15.0)	3,306	(71.9)
30-39	623,784	(25.4)	2,658	(0.4)	1,576	614	468	(17.6)	2,190	(72.0)
40-49	342,796	(14.0)	1,216	(0.4)	673	298	245	(20.1)	971	(69.3)
50+	413,062	(16.8)	1,059	(0.3)	582	269	208	(19.6)	851	(68.4)
Missing/invalid	20,829	(0.8)	32	(0.2)	20	5	7	(21.9)	25	(80.0)
<b>Gender</b>										
Male	1,298,730	(53.0)	7,633	(0.6)	4,598	1,744	1,291	(16.9)	6,342	(72.5)
Female	1,121,306	(45.7)	1,274	(0.1)	694	361	219	(17.2)	1,055	(65.8)
Transgender	16,830	(0.7)	252	(1.5)	140	76	36	(14.3)	216	(64.8)
Another gender	1,771	(0.1)	9	(0.5)	6	3	0	(0.0)	9	(66.7)
Declined/not asked/unknown/missing	13,870	(0.6)	20	(0.1)	17	2	1	(5.0)	19	(89.5)
<b>Race/Ethnicity</b>										
American Indian or Alaska Native	16,074	(0.7)	64	(0.4)	40	15	9	(14.1)	55	(72.7)
Asian	60,207	(2.5)	152	(0.3)	88	35	29	(19.1)	123	(71.5)
Black or African American	976,578	(39.8)	4,256	(0.4)	2,454	1,141	661	(15.5)	3,595	(68.3)
Hispanic or Latino	573,587	(23.4)	2,601	(0.5)	1,582	491	528	(20.3)	2,073	(76.3)
Native Hawaiian or Pacific Islander	4,599	(0.2)	18	(0.4)	13	2	3	(16.7)	15	(86.7)
White	674,548	(27.5)	1,726	(0.3)	1,073	399	254	(14.7)	1,472	(72.9)
Multi-race	23,852	(1.0)	151	(0.6)	99	32	20	(13.2)	131	(75.6)
Declined	29,282	(1.2)	47	(0.2)	26	13	8	(17.0)	39	(66.7)
Don't know/not asked	60,571	(2.5)	141	(0.2)	61	48	32	(22.7)	109	(56.0)
Missing/invalid	33,209	(1.4)	32	(0.1)	19	10	3	(9.4)	29	(65.5)
<b>Population group in non-health care facilities<sup>f</sup></b>										
Men who have sex with men and who inject drugs	6,499	(1.0)	143	(2.2)	80	29	34	(23.8)	109	(73.4)
Men who have sex with men	145,730	(23.0)	2,245	(1.5)	1,391	385	469	(20.9)	1,776	(78.3)
Transgender persons who inject drugs	875	(0.1)	12	(1.4)	5	5	2	(16.7)	10	(50.0)
Transgender persons	7,896	(1.2)	128	(1.6)	74	37	17	(13.3)	111	(66.7)
Persons who inject drugs	45,167	(7.1)	148	(0.3)	71	46	31	(20.9)	117	(60.7)

Characteristics	HIV tests				Linkage to HIV medical care in 30 days <sup>c</sup>					
	All tests <sup>a</sup>	Percent of all tests (%)	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>d</sup>	Reported percentage <sup>e</sup> (%)
Heterosexual men	159,593	(25.2)	354	(0.2)	191	84	79	(22.3)	275	(69.5)
Heterosexual women	172,215	(27.2)	275	(0.2)	156	67	52	(18.9)	223	(70.0)
Women who have sex with women	8,392	(1.3)	5	(0.1)	2	0	3	(60.0)	2	(100.0)
Sex with a transgender person	989	(0.2)	6	(0.6)	5	0	1	(16.7)	5	(100.0)
No sexual contact or injection drug use	39,953	(6.3)	131	(0.3)	70	33	28	(21.4)	103	(68.0)
Missing/invalid	45,448	(7.2)	109	(0.2)	38	55	16	(14.7)	93	(40.9)
<b>Region</b>										
Northeast	383,488	(15.6)	1,240	(0.3)	995	174	71	(5.7)	1,169	(85.1)
Midwest	264,203	(10.8)	767	(0.3)	489	143	135	(17.6)	632	(77.4)
South	1,449,001	(59.1)	5,301	(0.4)	2,860	1,373	1,068	(20.1)	4,233	(67.6)
West	336,304	(13.7)	1,745	(0.5)	1,000	476	269	(15.4)	1,476	(67.8)
U.S. dependent areas	19,511	(0.8)	135	(0.7)	111	20	4	(3.0)	131	(84.7)
<b>Testing site type</b>										
Health care facilities	1,752,586	(71.5)	5,374	(0.3)	3,316	1,300	758	(14.1)	4,616	(71.8)
Non-health care facilities	632,757	(25.8)	3,556	(0.6)	2,083	741	732	(20.6)	2,824	(73.8)
Mobile units	54,401	(2.2)	245	(0.5)	52	140	53	(21.6)	192	(27.1)
Missing	12,763	(0.5)	13	(0.1)	4	5	4	(30.8)	9	(44.4)
<b>Total</b>	<b>2,452,507</b>	<b>(100.0)</b>	<b>9,188</b>	<b>(0.4)</b>	<b>5,455</b>	<b>2,186</b>	<b>1,547</b>	<b>(16.8)</b>	<b>7,641</b>	<b>(71.4)</b>

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb® as of September 15, 2020.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>c</sup> A person is considered linked to HIV medical care within 30 days if they have attended an appointment for HIV medical care within 30 days of diagnosis.

<sup>d</sup> Number of persons with newly diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days. This is the denominator used to calculate the reported percentage.

<sup>e</sup> Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").

<sup>f</sup> Restricted to non-health care settings because data on population groups are required in non-health care settings, but only required for HIV-positive tests in health care settings. Categories are mutually exclusive and based on behavioral risk in past 12 months under the old NHM&E reporting requirements and in past 5 years under the new requirements.

**Table 5. CDC-funded HIV testing and interview for partner services among persons newly diagnosed with HIV, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019**

CDC-funded Jurisdiction	HIV tests			Interview for Partner Services					
	All HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Interviewed	Not interviewed	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>c</sup>	Reported percentage <sup>d</sup>
Alabama	80,027	233	(0.3)	186	35	12	(5.2)	221	(84.2)
Alaska	1,678	3	(0.2)	3	0	0	(0.0)	3	(100.0)
Arizona	60,880	225	(0.4)	175	17	33	(14.7)	192	(91.1)
Arkansas	5,340	6	(0.1)	1	1	4	(66.7)	2	(50.0)
California									
Los Angeles	132,345	859	(0.6)	24	14	821	(95.6)	38	(63.2)
San Francisco	30,577	70	(0.2)	38	23	9	(12.9)	61	(62.3)
California (excludes Los Angeles and San Francisco)	35,356	259	(0.7)	104	124	31	(12.0)	228	(45.6)
Colorado	1,616	10	(0.6)	8	1	1	(10.0)	9	(88.9)
Connecticut	70,260	93	(0.1)	80	13	0	(0.0)	93	(86.0)
Delaware	10,857	21	(0.2)	15	6	0	(0.0)	21	(71.4)
District of Columbia	27,059	160	(0.6)	36	49	75	(46.9)	85	(42.4)
Florida	242,643	1,210	(0.5)	754	167	289	(23.9)	921	(81.9)
Georgia	133,001	808	(0.6)	350	70	388	(48.0)	420	(83.3)
Hawaii	3,227	3	(0.1)	3	0	0	(0.0)	3	(100.0)
Idaho	3,703	9	(0.2)	8	0	1	(11.1)	8	(100.0)
Illinois									
Chicago	52,992	75	(0.1)	20	16	39	(52.0)	36	(55.6)
Illinois (excludes Chicago)	2,879	4	(0.1)	3	0	1	(25.0)	3	(100.0)
Indiana	25,196	4	(0.0)	4	0	0	(0.0)	4	(100.0)
Iowa	11,668	16	(0.1)	16	0	0	(0.0)	16	(100.0)
Kansas	18,132	43	(0.2)	39	4	0	(0.0)	43	(90.7)
Kentucky	18,908	10	(0.1)	8	0	2	(20.0)	8	(100.0)
Louisiana	117,600	342	(0.3)	152	4	186	(54.4)	156	(97.4)
Maine	1,840	5	(0.3)	5	0	0	(0.0)	5	(100.0)
Maryland									
Baltimore	46,148	131	(0.3)	71	46	14	(10.7)	117	(60.7)
Maryland (excludes Baltimore)	39,119	64	(0.2)	49	15	0	(0.0)	64	(76.6)
Massachusetts	42,222	117	(0.3)	81	7	29	(24.8)	88	(92.0)
Michigan	47,346	170	(0.4)	148	19	3	(1.8)	167	(88.6)
Minnesota	4,318	8	(0.2)	2	0	6	(75.0)	2	(100.0)
Mississippi	50,312	202	(0.4)	168	26	8	(4.0)	194	(86.6)
Missouri	54,980	156	(0.3)	139	12	5	(3.2)	151	(92.1)
Montana	2,563	0	----	0	0	0	----	0	----
Nebraska	8,436	26	(0.3)	13	0	13	(50.0)	13	(100.0)
Nevada	24,812	167	(0.7)	137	14	16	(9.6)	151	(90.7)

CDC-funded Jurisdiction	HIV tests			Interview for Partner Services					
	All HIV tests <sup>a</sup>	Newly diagnosed HIV-positive tests <sup>b</sup>	Newly diagnosed HIV positivity (%)	Interviewed	Not interviewed	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>c</sup>	Reported percentage <sup>d</sup>
New Hampshire	1,260	5	(0.4)	3	1	1	(20.0)	4	(75.0)
New Jersey	26,598	140	(0.5)	25	8	107	(76.4)	33	(75.8)
New Mexico	8,090	34	(0.4)	31	3	0	(0.0)	34	(91.2)
New York									
New York City	91,283	430	(0.5)	191	71	168	(39.1)	262	(72.9)
New York (excludes New York City)	25,323	127	(0.5)	94	16	17	(13.4)	110	(85.5)
North Carolina	40,778	85	(0.2)	70	13	2	(2.4)	83	(84.3)
North Dakota	5,609	7	(0.1)	6	1	0	(0.0)	7	(85.7)
Ohio	16,718	232	(1.4)	207	13	12	(5.2)	220	(94.1)
Oklahoma	4,579	19	(0.4)	6	3	10	(52.6)	9	(66.7)
Oregon	10,404	41	(0.4)	30	2	9	(22.0)	32	(93.8)
Pennsylvania									
Philadelphia	48,275	164	(0.3)	68	29	67	(40.9)	97	(70.1)
Pennsylvania (excludes Philadelphia)	73,301	155	(0.2)	134	21	0	(0.0)	155	(86.5)
Rhode Island	2,788	2	(0.1)	2	0	0	(0.0)	2	(100.0)
South Carolina	62,884	272	(0.4)	193	25	54	(19.9)	218	(88.5)
South Dakota	1,606	1	(0.1)	1	0	0	(0.0)	1	(100.0)
Tennessee	111,836	326	(0.3)	233	53	40	(12.3)	286	(81.5)
Texas									
Houston	97,090	398	(0.4)	40	7	351	(88.2)	47	(85.1)
Texas (excludes Houston)	288,729	765	(0.3)	397	149	219	(28.6)	546	(72.7)
Utah	2,384	8	(0.3)	8	0	0	(0.0)	8	(100.0)
Vermont	338	2	(0.6)	2	0	0	(0.0)	2	(100.0)
Virginia	65,586	223	(0.3)	165	34	24	(10.8)	199	(82.9)
Washington	14,471	57	(0.4)	33	20	4	(7.0)	53	(62.3)
West Virginia	6,505	26	(0.4)	14	1	11	(42.3)	15	(93.3)
Wisconsin	14,323	25	(0.2)	22	2	1	(4.0)	24	(91.7)
Wyoming	4,198	0	----	0	0	0	----	0	----
Puerto Rico	17,631	128	(0.7)	105	12	11	(8.6)	117	(89.7)
U.S. Virgin Islands	1,880	7	(0.4)	1	0	6	(85.7)	1	(100.0)
<b>Total</b>	<b>2,452,507</b>	<b>9,188</b>	<b>(0.4)</b>	<b>4,921</b>	<b>1,167</b>	<b>3,100</b>	<b>(33.7)</b>	<b>6,088</b>	<b>(80.8)</b>

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHM&E) data reported through EvaluationWeb<sup>®</sup> as of September 15, 2020.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A newly diagnosed HIV-positive test refers to a person who has a current HIV-positive test result (includes unconfirmed preliminary positive rapid tests and confirmed positive tests) and no indication of a previous HIV-positive test.

<sup>c</sup> Number of persons with newly diagnosed HIV whose test records have valid and complete information on interview for Partner Services. This is the denominator used to calculate the reported percentage.

<sup>d</sup> Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").



**Table 6. CDC-funded HIV testing and linkage to HIV medical care among persons previously diagnosed with HIV not in HIV medical care, 60 jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2019**

CDC-funded Jurisdiction	Linkage to HIV Medical Care in 30 days <sup>d</sup>								
	All HIV tests <sup>a</sup>	Previously diagnosed HIV-positive tests <sup>b</sup>	Previously diagnosed HIV-positive tests not in care <sup>c</sup>	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>e</sup>	Reported percentage <sup>f</sup> (%)
Alabama	80,027	430	1	0	1	0	(0.0)	1	(0.0)
Alaska	1,678	0	0	0	0	0	----	0	----
Arizona	60,880	72	35	14	19	2	(5.7)	33	(42.4)
Arkansas	5,340	12	0	0	0	0	----	0	----
California									
Los Angeles	132,345	458	7	5	2	0	(0.0)	7	(71.4)
San Francisco	30,577	278	115	107	2	6	(5.2)	109	(98.2)
California (excludes Los Angeles and San Francisco)	35,356	115	51	37	11	3	(5.9)	48	(77.1)
Colorado	1,616	10	3	1	0	2	(66.7)	1	(100.0)
Connecticut	70,260	25	21	18	2	1	(4.8)	20	(90.0)
Delaware	10,857	13	0	0	0	0	----	0	----
District of Columbia	27,059	125	14	2	4	8	(57.1)	6	(33.3)
Florida	242,643	1,482	29	25	3	1	(3.4)	28	(89.3)
Georgia	133,001	293	125	68	35	22	(17.6)	103	(66.0)
Hawaii	3,227	0	0	0	0	0	----	0	----
Idaho	3,703	1	0	0	0	0	----	0	----
Illinois									
Chicago	52,992	227	47	23	7	17	(36.2)	30	(76.7)
Illinois (excludes Chicago)	2,879	0	0	0	0	0	----	0	----
Indiana	25,196	0	0	0	0	0	----	0	----
Iowa	11,668	3	1	0	1	0	(0.0)	1	(0.0)
Kansas	18,132	5	3	0	3	0	(0.0)	3	(0.0)
Kentucky	18,908	9	1	1	0	0	(0.0)	1	(100.0)
Louisiana	117,600	767	17	13	0	4	(23.5)	13	(100.0)
Maine	1,840	0	0	0	0	0	----	0	----
Maryland									
Baltimore	46,148	408	52	5	41	6	(11.5)	46	(10.9)
Maryland (excludes Baltimore)	39,119	88	45	21	5	19	(42.2)	26	(80.8)
Massachusetts	42,222	513	118	52	57	9	(7.6)	109	(47.7)
Michigan	47,346	107	83	56	18	9	(10.8)	74	(75.7)
Minnesota	4,318	15	4	0	1	3	(75.0)	1	(0.0)
Mississippi	50,312	103	14	9	4	1	(7.1)	13	(69.2)
Missouri	54,980	180	76	29	28	19	(25.0)	57	(50.9)
Montana	2,563	0	0	0	0	0	----	0	----
Nebraska	8,436	8	3	0	3	0	(0.0)	3	(0.0)
Nevada	24,812	160	46	25	16	5	(10.9)	41	(61.0)

CDC-funded Jurisdiction				Linkage to HIV Medical Care in 30 days <sup>d</sup>					
	All HIV tests <sup>a</sup>	Previously diagnosed HIV-positive tests <sup>b</sup>	Previously diagnosed HIV-positive tests not in care <sup>c</sup>	Linked	Not linked	Missing/invalid	Missing/invalid (%)	Denominator for reported percentage <sup>e</sup>	Reported percentage <sup>f</sup> (%)
New Hampshire	1,260	0	0	0	0	0	----	0	----
New Jersey	26,598	123	19	11	7	1	(5.3)	18	(61.1)
New Mexico	8,090	18	6	1	5	0	(0.0)	6	(16.7)
New York									
New York City	91,283	371	180	147	16	17	(9.4)	163	(90.2)
New York (excludes New York City)	25,323	251	21	18	3	0	(0.0)	21	(85.7)
North Carolina	40,778	184	24	9	8	7	(29.2)	17	(52.9)
North Dakota	5,609	6	5	4	1	0	(0.0)	5	(80.0)
Ohio	16,718	73	39	22	12	5	(12.8)	34	(64.7)
Oklahoma	4,579	5	5	5	0	0	(0.0)	5	(100.0)
Oregon	10,404	16	3	1	2	0	(0.0)	3	(33.3)
Pennsylvania									
Philadelphia	48,275	257	82	47	22	13	(15.9)	69	(68.1)
Pennsylvania (excludes Philadelphia)	73,301	492	343	38	305	0	(0.0)	343	(11.1)
Rhode Island	2,788	1	0	0	0	0	----	0	----
South Carolina	62,884	133	50	23	26	1	(2.0)	49	(46.9)
South Dakota	1,606	0	0	0	0	0	----	0	----
Tennessee	111,836	613	243	92	135	16	(6.6)	227	(40.5)
Texas									
Houston	97,090	904	448	171	57	220	(49.1)	228	(75.0)
Texas (excludes Houston)	288,729	1,549	367	158	207	2	(0.5)	365	(43.3)
Utah	2,384	1	1	0	0	1	(100.0)	0	----
Vermont	338	0	0	0	0	0	----	0	----
Virginia	65,586	123	17	7	7	3	(17.6)	14	(50.0)
Washington	14,471	8	0	0	0	0	----	0	----
West Virginia	6,505	18	1	0	0	1	(100.0)	0	----
Wisconsin	14,323	18	8	4	4	0	(0.0)	8	(50.0)
Wyoming	4,198	0	0	0	0	0	----	0	----
Puerto Rico	17,631	89	42	28	8	6	(14.3)	36	(77.8)
U.S. Virgin Islands	1,880	5	1	1	0	0	(0.0)	1	(100.0)
<b>Total</b>	<b>2,452,507</b>	<b>11,165</b>	<b>2,816</b>	<b>1,298</b>	<b>1,088</b>	<b>430</b>	<b>(15.3)</b>	<b>2,386</b>	<b>(54.4)</b>

Data Source: Centers for Disease Control and Prevention National HIV Prevention Program Monitoring and Evaluation (NHME) data reported through EvaluationWeb<sup>®</sup> as of September 15, 2020.

<sup>a</sup> Includes only tests with negative or positive results; tests with discordant or indeterminate results are excluded.

<sup>b</sup> A previously diagnosed HIV-positive test is a test on a client who was previously reported to the HIV surveillance system or who reports a previous positive HIV test or evidence of a previous positive test is found on review of other data sources.

<sup>c</sup> Excludes persons already in HIV medical care.

<sup>d</sup> A person is considered linked to HIV medical care within 30 days if they have attended an appointment for HIV medical care within 30 days of the current test.

<sup>e</sup> Number of persons with previously diagnosed HIV whose test records have valid and complete information on attendance and date of first appointment for HIV medical care within 30 days. This is the denominator used to calculate the reported percentage.

<sup>f</sup> Reported percentage excludes tests without data to calculate the outcome (i.e., invalid, missing, or "Don't Know").